SUTRO BIOPHARMA INC (STRO)

Company Profile

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 298 full-time employees. The company went IPO on 2018-09-27. The firm is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The company provides two wholly owned ADCs in the clinic, namely luveltamab tazevibulin (STRO-002 or luvelta) and STRO-001. STRO-002 is an ADC directed against folate receptor-alpha (FolRa) for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. STRO-001 is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma (NHL). Its preclinical product candidate, STRO-003, is a single homogeneous ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), developed for the treatment of solid tumors.

Company Info

SUTRO BIOPHARMA INC

111 Oyster Point Blvd.

South San Francisco CALIFORNIA 94080

P: 16503928412

CEO: William J. Newell

Employees: 298

Website: https://www.sutrobio.com/